FDA approves Roche leukaemia treatment
Genentech, a US subsidiary of Roche, has obtained approval from the United States Food and Drug Administration (FDA) for a treatment for chronic lymphocytic leukaemia (CLL).
Select your language
Generated with artificial intelligence.
Listening:
FDA approves Roche leukaemia treatment
+ Get the most important news from Switzerland in your inbox
The combination of Venclexta (venetoclax) with acalabrutinib may be offered to patients suffering from this slowly progressing form of blood cancer, Genentech said on Friday.
The new treatment regimen gives patients another option in addition to the established treatment of Venclexta and Gazyva. What’s more, the new combination is a time-limited therapy and the drugs are administered orally only.
According to a phase III clinical trial, the new treatment works better than chemotherapy, reducing the risk of disease progression and death by 35% compared with chemotherapy.
Chronic lymphocytic leukaemia (CLL) is the most common form of leukaemia in adults. It is estimated that 22,760 new cases will be diagnosed in the United States in 2026.
More
Novartis makes progress with myeloid leukaemia drug
Translated from French with AI/mga
We select the most relevant news for an international audience and use automatic translation tools to translate them into English. A journalist then reviews the translation for clarity and accuracy before publication.
Providing you with automatically translated news gives us the time to write more in-depth articles. The news stories we select have been written and carefully fact-checked by an external editorial team from news agencies such as Bloomberg or Keystone.
If you have any questions about how we work, write to us at english@swissinfo.ch.
External Content
In compliance with the JTI standards
More: SWI swissinfo.ch certified by the Journalism Trust Initiative
You can find an overview of ongoing debates with our journalists here . Please join us!
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.